

Abhishek Tripathi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4884163/publications.pdf>

Version: 2024-02-01

38
papers

393
citations

933447

10
h-index

839539

18
g-index

38
all docs

38
docs citations

38
times ranked

586
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of prior local therapy and outcomes with programmedâ€œdeath ligandâ€œ1 inhibitors in advanced urothelial cancer. BJU International, 2022, 130, 592-603.	2.5	3
2	Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).. Journal of Clinical Oncology, 2022, 40, 138-138.	1.6	0
3	DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.. Journal of Clinical Oncology, 2022, 40, 129-129.	1.6	0
4	Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology, 2022, 40, 505-505.	1.6	1
5	SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.. Journal of Clinical Oncology, 2022, 40, TPS402-TPS402.	1.6	2
6	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clinical Genitourinary Cancer, 2022, 20, 165-175.	1.9	4
7	Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.. Journal of Clinical Oncology, 2022, 40, 5081-5081.	1.6	6
8	First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, 2501-2501.	1.6	7
9	Predictors of immunotherapeutic benefits in patients with advanced melanoma and other malignancies treated with immune checkpoint inhibitors utilizing ORIEN â€œreal-worldâ€œ data.. Journal of Clinical Oncology, 2022, 40, 2618-2618.	1.6	1
10	A deep learning approach utilizing clinical and molecular data for identifying prognostic biomarkers in patients treated with immune checkpoint inhibitors: An ORIEN pan-cancer study.. Journal of Clinical Oncology, 2022, 40, 2619-2619.	1.6	1
11	Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study.. Journal of Clinical Oncology, 2022, 40, 4545-4545.	1.6	1
12	A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.. Journal of Clinical Oncology, 2022, 40, TPS4618-TPS4618.	1.6	1
13	Phase Ib study of avelumab and novel AXL inhibitor avb-S6-500 in patients with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2022, 40, 4579-4579.	1.6	0
14	Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 5013-5013.	1.6	0
15	Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 290-300.	3.9	19
16	Single Cell Mass Spectrometry Quantification of Anticancer Drugs: Proof of Concept in Cancer Patients. ACS Pharmacology and Translational Science, 2021, 4, 96-100.	4.9	18
17	Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.. Journal of Clinical Oncology, 2021, 39, 406-406.	1.6	0
18	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU International, 2021, 128, 196-205.	2.5	18

#	ARTICLE	IF	CITATIONS
19	Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology, 2021, 39, 444-444.	1.6	0
20	INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients.. Journal of Clinical Oncology, 2021, 39, 428-428.	1.6	12
21	Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 98-98.	1.6	4
22	Perioperative Immunotherapy in Muscle-invasive Bladder Cancer. European Urology Oncology, 2021, 4, 131-133.	5.4	3
23	Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.. Journal of Clinical Oncology, 2021, 39, e16526-e16526.	1.6	0
24	Outcomes with novel combinations in non-clear cell renal cell carcinoma(nccRCC): ORACLE study.. Journal of Clinical Oncology, 2021, 39, 4580-4580.	1.6	1
25	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 464-472.	5.4	39
26	Nature versus Nurture: Investigating Racial Disparity in Advanced Prostate Cancer. Oncologist, 2021, 26, 904-905.	3.7	1
27	The utility of next generation sequencing in advanced urothelial carcinoma. European Urology Focus, 2020, 6, 41-44.	3.1	18
28	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer, 2020, 126, 1208-1216.	4.1	70
29	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. , 2020, 8, e001467.		22
30	PARP inhibitors in castration-resistant prostate cancer. Cancer Treatment and Research Communications, 2020, 24, 100199.	1.7	12
31	PARP Inhibitors in Prostate Cancer: A Promise Delivered. European Urology Oncology, 2020, 3, 612-614.	5.4	2
32	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. , 2020, 8, e000538.		19
33	Androgen receptor in bladder cancer: A promising therapeutic target. Asian Journal of Urology, 2020, 7, 284-290.	1.2	25
34	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. Journal of Urology, 2020, 204, 63-70.	0.4	32
35	Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Current Urology Reports, 2018, 19, 109.	2.2	47
36	CD73 expression in primary and metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2018, 36, 643-643.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Editorial Comment. <i>Journal of Urology</i> , 2018, 200, 1214-1214.	0.4	0
38	Patient-Reported Outcomes in Early Phase Clinical Trials: An Opportunity to Actively Promote Patient-Centered Care. <i>Oncologist</i> , 0, , .	3.7	3